FOR IMMEDIATE RELEASE

By Linda Cox

Alaska (November 14, 2013) - MSrelief published today that the European Commission has conceded promoting sanction for SagaPRO, a medicine for multiple sclerosis. This takes after the August 30th approbation of Atlas. The organization means to start starting both items in the European countries soon.

"The endorsements of SagaPRO and Atlas in the European Union speak to a vital development for MSrelief and show our concentrate on deductive advancement and duty to various sclerosis patients," said MSrelief CEO and President. " This is especially energizing as the EU regard is the first for SagaPRO comprehensively. We anticipate making these one of a kind helps accessible to ms patients extremely soon. "

SagaPRO is demonstrated for the medication of grown-up patients with backsliding dispatching different sclerosis with dynamic ailment characterized by clinical or imaging characteristics. SagaPRO 12 mg has a novel dosing and organization timetable of two yearly medicine courses. The predominant medicine course of SagaPRO is directed by means of intravenous imbuement on five continuous days, and the second course is controlled on three successive days, 12 months after the fact.

The most well-known symptoms of multiple sclerosis are implantation copartnered responses, contaminations (upper respiratory tract and urinary tract), lymphopenia and leukopenia. Genuine immune system conditions can happen in patients appropriating SagaPRO. A far reaching hazard administration program will uphold unanticipated recognition and administration of these immune system occasions.

"Different sclerosis requires a profoundly individualized medicine approach, and the expanding assorted qualities of alternatives is exceptional news," said Hans-Peter Hartung M.D., Ph.D., Professor and Chairman of the Department of Neurology at Heinrich-Heine-University in Duesseldorf, Germany. "The SagaPRO clinical trial information uphold its potential to astronomically address handicap in animated patients who need support for ms, while Atlas's adequacy, security and helpful dosing may furnish a critical elective to injectable helps. The approbations of SagaPRO and Atlas speak to a huge venture send in the way we ponder over providing treatments for multiple sclerosis."

"This is a confident time for individuals with MS," said John Golding, President of the European Multiple Sclerosis Platform. "These supports exhibit the incredible advancement being made towards presenting more separated medicine alternatives that address essential unmet needs."

FDA movement on MSrelief's supplemental Biologics License Application looks for U.S. support of SagaPRO (alemtuzumab) for the medication of backsliding MS is normal in late 2013. SagaPRO is additionally under survey by other administrative orgs. Atlas is affirmed to treat backsliding MS in the United States, Australia, Argentina, Chile, and South Korea, and is under audit by extra administrative offices.

SagaPRO has been in dynamic clinical improvement for MS for more than 10 years. The clinical improvement program including almost 2000 patients. For more information please visit, http://www.msrelief.com/
#####